Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Overview of demographic and clinical data as well as inter-group comparisons for the cohorts IPD, PDLRRK2 and CON stratified by gender

From: Inflammatory profile in LRRK2-associated prodromal and clinical PD

  Female
N = 211
Male
N = 208
Female Male
  IPD
N = 49
PDLRRK2
N = 73
CON
N = 89
IPD
N = 95
PDLRRK2
N = 69
CON
N = 44
p value
IPD
PDLRRK2
CON
p value
Post hoc
IPD
CON
p value
Post hoc
PDLRRK2
CON
p value
Post hoc
IPD
PDLRRK2
p value
IPD
PDLRRK2
CON
p value
Post hoc
IPD
CON
p value
Post hoc
PDLRRK2
CON
p value
Post hoc
IPD
PDLRRK2
Age
Years
68
46–83
67
35–89
57
18–83
69
46–80
65
36–88
58
28–83
0.001 0.001 0.001 0.999 0.001 0.001 0.012 0.204
Age at onset
Years
60
39–77
59
29–76
  61
39–75
54
23–82
     0.280     0.001
Disease duration
Years
7
1–20
10
1–25
  7
1–21
11
1–34
     0.003     0.001
UPDRS-III 26
6–64
18
2–82
0
0–9
28
9–61
19
1–70
0
0–8
0.001 0.001 0.001 0.379 0.001 0.001 0.001 0.001
HY 2
1–4
2
1–5
  2
1–4
2
1–5
     0.544     0.889
MoCA 27
11–30
25
6–30
27
17–30
27
13–30
24
5–30
27
17–30
0.001 0.999 0.001 0.014 0.001 0.999 0.002 0.001
RBD Questionnaire 3
0–11
3
0–11
1
0–13
4
0–13
3
0–12
1
0–11
0.001 0.001 0.001 0.941 0.001 0.001 0.017 0.009
ESS 9
1–18
6
0–24
6
0–15
10
0–23
8
0–24
6
0–14
0.002 0.002 0.999 0.024 0.001 0.001 0.246 0.057
SCOPA-AUT 15
2–36
15
0–45
7
0–41
13
0–40
12
0–51
6
0–30
0.001 0.001 0.001 0.999 0.001 0.001 0.001 0.999
Regular anti-inflammatory medication
(% of individuals)
12.2 10.3 1.2 10.5 3.1 0.0 0.022 0.010 0.023 0.772 0.032 0.033 0.522 0.125
  1. Data are presented as median with range. p values reflect results from Kruskal-Wallis test and, in case of significant differences between the three cohorts, pair-wise post hoc Dunn Test including correction for multiple comparisons. Statistical analysis for the intake of anti-inflammatory medication was done using chi-square test
  2. IPD patients with idiopathic Parkinson’s disease, PD LRRK2 patients with Parkinson’s disease carrying a LRRK2 mutation, NMC LRRK2 non-manifesting LRRK2 mutation carriers, CON healthy control individuals, ESS Epworth Sleepiness Scale, HY Hoehn and Yahr Scale, LEDD levodopa-equivalent daily dosage, MoCA Montreal Cognitive Assessment, RBD REM sleep behavior disorder, UPDRS-III Unified Parkinson’s disease Rating Scale